Radiopharmaceuticals Market CAGR To Be 10.6% by 2040, Due to the Ongoing Advancements in Radioligand Therapies| Roots Analysis

According to our latest market report "Radiopharmaceuticals Market" by Purpose of Radiopharmaceutical, Type of Diagnostic Radiopharmaceuticals, Type of Emitter, Type of Radioisotope, Therapeutic Area, End-users, Geographical Regions and Key Players: Industry Trends and Global Forecasts, Till 2040", the global radiopharmaceutical market size is projected to reach USD 54.6 billion by 2040 from USD 12.1 billion in 2025, growing at a CAGR of 10.6% in the forecast period 2025-2040.

To request quote of this report, please visit: https://www.rootsanalysis.com/reports/radiopharmaceuticals-market/request-quote.html

Radiopharmaceuticals are specialized drugs containing radioisotopes and are used primarily in diagnostic imaging and targeted therapy. These drugs emit radiation like alpha, beta or gamma, that are detected by imaging equipment such as PET and SPECT scanners. This enables precise visualization and functional evaluation of organs, tissues, and physiological processes within the body. Radiopharmaceuticals are widely used in the management of various disorders including oncological disorders, cardiovascular disorders, neurological disorders. These facilitate early diagnosis, disease monitoring, and personalized treatment and improved patient outcomes. Given the growing use of radiopharmaceuticals across a wide range of clinical indications and the ongoing technological advancements (including PET scanners, alpha therapies), the radiopharmaceutical industry is anticipated to become one of the fastest growing markets within the pharmaceutical industry in the coming years.

Radiopharmaceuticals Market Segments
Based on the purpose of radiopharmaceutical, the market is segmented into Diagnostics and Therapeutics.

1. The diagnostics segment led the global radiopharmaceutical market, capturing the largest revenue share of more than 50% in the current year.
2. The therapeutic segment is anticipated to show a higher growth rate of 13.3%, during the forecast period.

Based on the type of diagnostic radiopharmaceutical, the market is segmented into PET radiopharmaceuticals and SPECT radiopharmaceuticals.

1. The SPECT radiopharmaceutical segment led the global radiopharmaceutical market, capturing the largest revenue share of close to 70% in the current year.
2. The PET radiopharmaceutical segment is anticipated to show the highest growth rate of 11.8%, during the forecast period.

To request a sample copy / brochure of this report, please visit https://www.rootsanalysis.com/reports/radiopharmaceuticals-market/request-sample.html

Based on the type of emitter, the market is segmented into gamma emitters, beta emitters and other emitters.

1. The gamma emitters segment led the global radiopharmaceutical market, capturing the largest revenue share of over 75% in the current year.
2. The beta emitters segment is anticipated to be the fastest growing segment in this industry, with an annualized rate of 12.6% during the forecast period.

Based on the type of radioisotope, the market is segmented into Technetium-99m, Fluorine-18, Iodine-131, Leutetium-177, Gallium-68 and Other Radioisotopes.

1. The Technetium-99m radioisotope segment led the global radiopharmaceuticals market, capturing the largest revenue share of around 80% in the current year.
2. The Leutetium-177 radioisotope segment is anticipated to show the highest growth rate of 15.0% during the forecast period.

Based on the therapeutic area, the market is segmented into Oncological Disorders, Cardiovascular Disorders, Neurological Disorders, Hormonal Disorders, Gastrointestinal Disorders and Other Disorders.

1. The oncological disorders segment led the global radiopharmaceuticals market, capturing the largest revenue share of around 40% in the current year.
2. The neurological disorders segment is anticipated to be the fastest growing segment in this industry, with an annualized rate of 11.5% during the forecast period.

Based on end users, the market is segmented into Hospitals, Diagnostic Centers and Research Institutes.

1. The hospitals segment led the global radiopharmaceuticals market, capturing the largest revenue share of close to 50% in the current year.
2. The research institutes segment is anticipated to be the fastest growing segment in this industry, with an annualized rate of 11.4% during the forecast period.

Based on the regional insights, the market is segmented into North America, Europe, Asia-Pacific, Middle East and Africa, and Latin America.

1. North America dominated the global radiopharmaceuticals market and accounted for the largest revenue share of around 45% in the current year.
2. In Asia-Pacific region, the global radiopharmaceuticals market is anticipated to be the fastest growing segment in this industry, with an annualized rate of 12.0%, during the forecast period.

Browse Full Report Description + Research Methodology + Table of Content + Infographics here:
https://www.rootsanalysis.com/reports/radiopharmaceuticals-market.html

Radiopharmaceuticals Market Regional Outlook
Based on the geographical regions, the radiopharmaceuticals market can be segmented into five major regions, including North America, Europe, Asia Pacific, Latin America and Middle East and North Africa. Led by the US, North America is anticipated to capture the majority share in the radiopharmaceuticals market in 2025. The Asia Pacific is accounted to be the fastest-growing segment of the market. The growth of the manufacturing market in this region is primarily driven by increasing healthcare investments, a growing geriatric population, rising prevalence of cancer, and expanding access to advanced diagnostic and therapeutic technologies in the region.

Key Report Takeaways
1. The current market landscape is highly fragmented, featuring the presence of both new entrants and established players; of these, more than 45% of the radioactive drug developers are based in North America
2. Over 410 radiopharmaceuticals are currently being investigated across various stages of development for the treatment of various disorders, particularly cancer; of these, close to 30% of the drugs are alpha emitters
3. Around 25% of the deals inked in this domain were focused on the supply of radioisotopes; majority of the intercontinental deals were signed by players based in North America
4. Currently, over 35% of the market is expected to be captured by revenues generated from radiopharmaceuticals for oncological disorders; further, market for Lu-177 labelled radioactive drugs is likely to grow at a faster pace

Radiopharmaceuticals Market Key Players
Examples of key companies engaged in the radiopharmaceuticals market (which have also been profiled in this market report; the complete list of companies is available in the full report) include Bayer, Bracco, Eli Lilly, GE HealthCare, ITM Isotope Technologies, Jubilant Radiopharma, Lantheus, Novartis and Telix Pharmaceuticals

Gaurav Chaudhary
Email: Gaurav.chaudhary@rootsanalysis.com or sales@rootsanalysis.com
Website: https://www.rootsanalysis.com

Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. All reports provided by us are structured in a way that enables the reader to develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we provide bespoke research / consulting services dedicated to serve our clients in the best possible way.

This release was published on openPR.